Tlr9 - toll-like receptor 9 Gene

Mus musculus

Gene ID: 81897 | Gene type: protein coding

About Tlr9

Chromosome 9: 106,099,797-106,104,082 forward strand.GRCm39:CM001002.3

This gene has 1 transcript (splice variant), 81 orthologues, 24 paralogues and is associated with 24 phenotypes. Biased expression in spleen adult (RPKM 37.8), mammary gland adult (RPKM 11.5) and 5 other tissues.

Summary

Predicted to enable interleukin-1 receptor binding activity; pattern recognition receptor activity; and siRNA binding activity. Involved in several processes, including positive regulation of cytokine production; regulation of defense response; and regulation of macromolecule biosynthetic process. Acts upstream of or within several processes, including cellular response to chloroquine; negative regulation of ERK1 and ERK2 cascade; and regulation of dendritic cell cytokine production. Located in cytoplasmic vesicle; endoplasmic reticulum; and plasma membrane. Is expressed in intestine and small intestine mucosa. Human ortholog(s) of this gene implicated in several diseases, including allergic bronchopulmonary aspergillosis; cystic fibrosis; glomerulonephritis (multiple); hepatitis B; and lung disease (multiple). Orthologous to human TLR9 (toll like receptor 9). [provided by Alliance of Genome Resources, Apr 2022]

Tlr9 Products(1)

mRNA	Protein	Name
NM_031178.2	NP_112455.2	toll-like receptor 9 precursor

Tlr9 Protein Structure

PRK15370

LRR_RI

PLN00113

LRR_RI

LRR_12

LRR_RI

LRR_8

LRR_RI

TIR_2

0
200
400
600
800
1032 a.a.

Protein Preferred Names

Protein Names

toll-like receptor 9

Recombinant Tlr9 Proteins

Cat. No.	Product Name	Accession	Purity
HY-P79302	TLR9 Protein, Mouse (CHO, mFc)	AAK29625 (L26-D818)	≥95%

Related Agents

Approval

Bioactive Molecules (3)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-B1370	Hydroxychloroquine sulfate	Inhibitor	99.99%	Yes
HY-B1370B	(R)-Hydroxychloroquine	Inhibitor	/	Unkown
HY-B1370A	(S)-Hydroxychloroquine	Inhibitor	/	Unkown

Clinical Phase

Bioactive Molecules (4)

Cat. No.	Product Name	Effect	Purity	Phase
HY-146244	Agatolimod	Agonist	/	Phase 3
HY-150218	Agatolimod sodium	Agonist	96.09%	Phase 3
HY-148511	Vidutolimod	Agonist	/	Phase 3
HY-150724	ODN 1018	Agonist	96.23%	Phase 2

Pre-clinical Phase

Bioactive Molecules (18)

Cat. No.	Product Name	Effect	Purity	Rare Diseases
HY-146245	ODN 1826	Agonist	/	Unkown
HY-150741	ODN 2216	Agonist	97.88%	Unkown
HY-124603	AT791	Inhibitor	98.77%	Unkown
HY-N0201	Atractylenolide I	Antagonist	99.87%	Unkown
HY-150743	ODN 2395	Agonist	98.39%	Unkown
HY-150726	ODN 1668	Agonist	≥99.0%	Unkown
HY-148045	TLR9-IN-1	Inhibitor	99.80%	Unkown
HY-101929	CU-CPT17e	Agonist	99.00%	Unkown
HY-150217	CpG ODN 10101	Agonist	94.06%	Unkown
HY-150736	ODN 20844	Inhibitor	96.52%	Unkown
HY-150750	ODN M362	Agonist	93.61%	Unkown
HY-146245C	ODN 1826 sodium	Agonist	98.79%	Unkown
HY-150745	ODN 24987	Inhibitor	/	Unkown
HY-150743C	ODN 2395 sodium	Agonist	/	Unkown
HY-12756	E6446	Antagonist	≥98.0%	Unkown
HY-150219	ODN M326	Agonist	/	Unkown
HY-B1370R	Hydroxychloroquine sulfate (Standard)	Inhibitor	/	Unkown
HY-150744	ODN 24888	Inhibitor	93.10%	Unkown

Orthologs Information

Species	Symbol	Source	ID
Homo sapiens	Tlr9	NCBI	NCBI:54106

Name
Email *

	Sorry, but the email address you supplied was invalid.